论文部分内容阅读
慢性粒细胞白血病 (ＣＭＬ)是由ＢＣＲ ＡＢＬ酪氨酸激酶肿瘤基因表达产物 ,即ｔ( 9;2 2 )Ｐｈ染色体易位引起。ＣＭＬ加速期患者疾病进展迅速 ,对目前的治疗无反应。Ｉｍａｔｉｎｉｂ为口服的ＢＣＲ ＡＢＬ激酶抑制剂。本研究报道 1 8个中心采用Ｉｍａｔｉｎｉｂ治疗加速期Ｃ
Chronic myeloid leukemia (CML) is caused by the translocation of the t (9; 2 2) Ph chromosome by the BCR ABL tyrosine kinase tumor gene expression product. Patients with accelerated CML are rapidly ailing and do not respond to current treatment. Imatinib is an oral BCR ABL kinase inhibitor. This study reported that 18 centers used Imatinib to treat accelerated phase C.